RUBICON RESEARCH LIMITED Share Price
RUBICON RESEARCH LIMITED Share Price Today
As of 25 Jul 2026, RUBICON RESEARCH LIMITED share price is ₹1,520.20. The stock opened at ₹1,529.70, compared to its previous close of ₹1,525.40. During today's trading session, RUBICON RESEARCH LIMITED share price moved in the range of ₹1,489.50 to ₹1,560.00, with an average price of ₹1,524.75 for the day. Looking at its last 52-week, the stock has touched a low of ₹570.75 and a high of ₹1,560.00. On the performance front, RUBICON RESEARCH LIMITED share price has increased by 133.86% over the last six months and is up 141.99% on a year-on-year basis.
RUBICON RESEARCH LIMITED Returns Calculator
RUBICON RESEARCH LIMITED Shareholder Returns
RUBICON RESEARCH LIMITED Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,68,842.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,93,860.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,92,687.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,12,593.00 | 33.55 | 3.27 | 11.27% | 0.00 | 14.95% | 423.36 | 0.93% | 0.44 | 43.52 |
| Zydus Lifesciences | 1,11,082.00 | 17.39 | 3.23 | 19.69% | 0.35 | 20.30% | 3.70 | 0.11% | 0.39 | 35.38 |
| Lupin | 1,09,553.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,05,607.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 97,364.90 | 30.58 | 2.56 | 11.07% | 0.18 | 12.54% | 377.96 | 0.69% | 0.41 | 38.68 |
| Aurobindo Pharma | 88,508.40 | 25.27 | 2.34 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 84,727.30 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
RUBICON RESEARCH LIMITED Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,284.27 | ₹853.89 | ₹393.52 | ₹313.57 |
| Other Income | ₹11.95 | ₹18.50 | ₹25.48 | ₹16.85 |
| Total Revenue | ₹1,296.22 | ₹872.39 | ₹419.00 | ₹330.42 |
| Total Expenses | ₹1,101.70 | ₹769.53 | ₹430.05 | ₹396.53 |
| Profit Before Tax | ₹194.52 | ₹102.86 | -₹11.05 | -₹66.11 |
| Tax | ₹60.16 | ₹11.85 | ₹5.84 | ₹1.01 |
| Profit After Tax | ₹134.36 | ₹91.01 | -₹16.89 | -₹67.12 |
| EPS - Basic | ₹8.82 | ₹5.98 | -₹1.11 | -₹4.41 |
| EPS - Diluted | ₹8.68 | ₹5.91 | -₹1.11 | -₹4.41 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹194.52 | ₹102.86 | -₹11.05 | -₹66.11 |
| Income before WC changes | ₹287.93 | ₹174.17 | ₹35.18 | -₹38.59 |
| Change in Assets | -₹244.21 | -₹241.49 | -₹162.98 | -₹36.16 |
| Change in Liabilities | ₹154.21 | ₹106.40 | ₹54.87 | ₹20.59 |
| Change in WC | -₹90.00 | -₹135.08 | -₹108.11 | -₹15.58 |
| Cash flow from Operations | ₹159.18 | ₹21.01 | -₹74.75 | -₹62.63 |
| Cash flow from Investing | -₹64.81 | -₹68.51 | -₹33.82 | -₹54.92 |
| Cash flow from Financing | -₹39.81 | ₹43.55 | ₹122.81 | ₹63.05 |
| Total Cash Flow | ₹54.56 | -₹3.95 | ₹14.24 | -₹54.50 |
| Cash (Start of the year) | ₹50.61 | ₹54.43 | ₹38.67 | ₹84.16 |
| Cash (End of the year) | ₹104.98 | ₹50.61 | ₹54.43 | ₹38.67 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹388.07 | ₹346.32 | ₹248.12 | ₹231.12 |
| Current Assets | ₹1,063.37 | ₹763.17 | ₹501.59 | ₹328.40 |
| Total Assets | ₹1,451.43 | ₹1,109.49 | ₹749.70 | ₹559.52 |
| Current Liabilities | ₹786.03 | ₹572.50 | ₹361.32 | ₹183.51 |
| Net Current Asset | ₹277.34 | ₹190.67 | ₹140.27 | ₹144.89 |
| Non-Current Liabilities | ₹124.42 | ₹151.99 | ₹102.01 | ₹70.61 |
| Equity Capital | ₹540.99 | ₹385.00 | ₹286.38 | ₹305.40 |
| Total Equity & Liabilities | ₹1,451.43 | ₹1,109.49 | ₹749.70 | ₹559.52 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,073.84 | ₹630.51 | ₹393.52 | ₹400.04 |
| Other Income | ₹19.68 | ₹26.43 | ₹25.48 | ₹17.38 |
| Total Revenue | ₹1,093.52 | ₹656.94 | ₹419.00 | ₹417.41 |
| Total Expenses | ₹870.24 | ₹622.87 | ₹430.05 | ₹400.49 |
| Profit Before Tax | ₹223.28 | ₹34.07 | -₹11.05 | ₹16.92 |
| Tax | ₹55.74 | ₹9.73 | ₹5.84 | ₹0.24 |
| Profit After Tax | ₹167.54 | ₹24.35 | -₹16.89 | ₹16.68 |
| EPS - Basic | ₹11.00 | ₹1.60 | -₹1.11 | ₹32.91 |
| EPS - Diluted | ₹10.82 | ₹1.58 | -₹1.11 | ₹32.91 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹223.28 | ₹34.07 | -₹11.05 | ₹16.92 |
| Income before WC changes | ₹291.63 | ₹85.60 | ₹35.18 | ₹44.02 |
| Change in Assets | -₹331.90 | -₹15.99 | -₹162.98 | -₹126.42 |
| Change in Liabilities | ₹96.78 | ₹29.47 | ₹54.87 | ₹20.88 |
| Change in WC | -₹235.12 | ₹13.49 | -₹108.11 | -₹105.54 |
| Cash flow from Operations | ₹29.65 | ₹83.20 | -₹74.75 | -₹71.10 |
| Cash flow from Investing | -₹10.03 | -₹130.49 | -₹33.82 | -₹52.21 |
| Cash flow from Financing | -₹34.05 | ₹45.86 | ₹122.81 | ₹65.22 |
| Total Cash Flow | -₹14.43 | -₹1.42 | ₹14.24 | -₹49.08 |
| Cash (Start of the year) | ₹40.47 | ₹41.76 | ₹38.67 | ₹78.65 |
| Cash (End of the year) | ₹25.85 | ₹40.47 | ₹54.43 | ₹29.57 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹390.61 | ₹446.09 | ₹248.12 | ₹280.31 |
| Current Assets | ₹950.32 | ₹570.51 | ₹501.59 | ₹398.03 |
| Total Assets | ₹1,340.94 | ₹1,016.60 | ₹749.70 | ₹678.34 |
| Current Liabilities | ₹588.54 | ₹431.25 | ₹361.32 | ₹180.67 |
| Net Current Asset | ₹361.78 | ₹139.26 | ₹140.27 | ₹217.36 |
| Non-Current Liabilities | ₹84.61 | ₹109.48 | ₹102.01 | ₹69.05 |
| Equity Capital | ₹667.79 | ₹475.87 | ₹286.38 | ₹428.61 |
| Total Equity & Liabilities | ₹1,340.94 | ₹1,016.60 | ₹749.70 | ₹678.34 |
About RUBICON RESEARCH LIMITED
Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.
RUBICON RESEARCH LIMITED Financial Highlights
- Revenue: RUBICON RESEARCH LIMITED reported revenue of ₹1,761.69 crore in FY26 vs ₹1,287.90 crore in FY25. It showed an increase of 36.79% on a yearly basis.
- Operating Profit: RUBICON RESEARCH LIMITED reported an operating profit of ₹320.53 crore in FY26 vs ₹194.52 crore in FY25. It showed an increase of 64.78% on a year-on-year basis.
- Net Profit: RUBICON RESEARCH LIMITED reported a net profit of ₹246.74 crore in FY26 vs ₹134.36 crore in FY25. It showed an increase of 83.64% on a yearly basis.
RUBICON RESEARCH LIMITED Quarterly Result Highlights
- RUBICON RESEARCH LIMITED reported revenue of ₹516.53 crore in Mar 2026, compared with ₹479.32 crore in Dec 2025, representing an increase of 7.76% on a quarter-on-quarter (QoQ) basis.
- RUBICON RESEARCH LIMITED reported an operating profit of ₹98.69 crore in Mar 2026, compared with ₹90.59 crore in Dec 2025, representing an increase of 8.94% on a quarter-on-quarter (QoQ) basis.
- RUBICON RESEARCH LIMITED reported a profit of ₹76.79 crore in Mar 2026, compared with ₹72.80 crore in Dec 2025, reflecting an increase of 5.48% on a QoQ basis.
- The earnings per share (EPS) of RUBICON RESEARCH LIMITED stood at ₹8.82 during Mar 2026.
Similar Stocks
FAQs on RUBICON RESEARCH LIMITED Share Price
What is RUBICON RESEARCH LIMITED share price today?
RUBICON RESEARCH LIMITED share price is ₹1,520.20 as on 24 Jul, 2026, 15:57 IST.
How has the RUBICON RESEARCH LIMITED share price performed in the past?
In the last 1 year, RUBICON RESEARCH LIMITED delivered a return of 141.99%. The RUBICON RESEARCH LIMITED share price hit a high of ₹1,560.00 and low of ₹570.75.
How much is the Mutual Fund shareholding in RUBICON RESEARCH LIMITED shares?
The Mutual Fund Shareholding in RUBICON RESEARCH LIMITED was 7.23% at the end of Jun 2026.
What is the the 52-week high and low of RUBICON RESEARCH LIMITED shares ?
The 52-week high and low of RUBICON RESEARCH LIMITED share is ₹1,560.00 and ₹570.75 as of 24 Jul, 2026.
What is the market cap of RUBICON RESEARCH LIMITED?
The market capitalisation of RUBICON RESEARCH LIMITED is ₹25,321.80 Crores as on 24 Jul, 2026.
What are the stock symbols of RUBICON RESEARCH LIMITED?
The stock symbol of RUBICON RESEARCH LIMITED is RUBICON on the NSE, 544578 on the BSE, and the ISIN is INE506V01022.
What was yesterday's closing price of RUBICON RESEARCH LIMITED shares ?
RUBICON RESEARCH LIMITED shares closed yesterday at ₹1,525.40 on NSE & ₹1,531.10 on BSE
How to buy RUBICON RESEARCH LIMITED shares?
To buy RUBICON RESEARCH LIMITED shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy RUBICON RESEARCH LIMITED shares on Holidays?
No, shares of RUBICON RESEARCH LIMITED or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell RUBICON RESEARCH LIMITED shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of RUBICON RESEARCH LIMITED?
The PE and PB ratio of RUBICON RESEARCH LIMITED is 102.62 and 19.65 respectively, as on 24 Jul, 2026, 15:57 IST.


